Nanoscope Therapeutics Inc.

Members of the Nanoscope Therapeutics Inc. leadership team will participate in one-on-one meetings with investors at the 2024 Leerink Partners Biopharma Private Company Connect, being held virtually on June 25-26, 2024. Participating will be CEO & Co-Founder Sulagna Bhattacharya, President & Co-Founder Samarendra Mohanty, Chief Medical Officer Samuel B Barone, MD, CFO Michael Marquez and VP Strategy & Business Development Jared Stephens. Nanoscope Therapeutics is developing gene-agnostic, sight-restoring optogenetic therapies for the millions of patients blinded by inherited retinal diseases, for which no cure exists. The company’s lead asset, MCO-010, recently announced the 100-week data from the RESTORE Phase 2b/3 multicenter, randomized, double-masked, sham-controlled clinical trial in the U.S. for retinitis pigmentosa (NCT04945772). The company has also recently completed the Phase 2 STARLIGHT trial of MCO-010 therapy in patients with Stargardt disease (NCT05417126 ). MCO-010 has received FDA fast-track designations and FDA orphan drug designations for both retinitis pigmentosa and Stargardt disease. Preclinical assets include non-viral laser-delivered MCO-020 gene therapy for geographic atrophies secondary to AMD. For more information visit nanostherapeutics.com #biotechnology #ophthalmology #genetherapy https://lnkd.in/gJkhm4d3

Nanoscope Therapeutics Inc. is proud to announce that Dr. Peter Kaiser, Professor of Ophthalmology at Cleveland Clinic Cole Eye Institute, will present the latest clinical trial results for MCO-010 at the Clinical Trials at the Summit Meeting on June 8th in Park City, Utah. Dr. Kaiser’s presentation will take place at 2:32pm MT. Nanoscope leadership will also be in attendance at the conference. Dr. Kaiser is a Scientific Advisor to Nanoscope and during his presentation, he will detail the results of the RESTORE Phase 2b/3 Study–MCO-010 for patients with Advanced retinitis pigementosa (RP), as well as the STARLIGHT Phase 2a Clinical Study (MCO-010 for patients with Stargardt Disease). For more information: nanostherapeutics.com Samarendra Mohanty Sulagna Bhattacharya Samuel B Barone #Ophthalmology #clinicaltrials #retinitispigmentosa #stargardt

For Nanoscope Therapeutics Inc. CEO and Co-Founder Sulagna Bhattacharya this has been a non-stop week at the Biotechnology Innovation Organization International Convention in San Diego. Today she gave a company presentation highlighting Nanoscope's Multi-Characteristic Opsin platform and an overview of the Company's mutation-agnostic approach. As a member of the BIO Board of Directors and Multiple BIO Committees, this has also been an opportunity to connect with BIO leadership colleagues. #BIO2024 #leadership #biotechnology #biopharma

Nanoscope Therapeutics Inc. CEO Sulagna Bhattacharya is heading to San Diego next week for Biotechnology Innovation Organization International Convention taking place June 3-6. Ms. Bhattacharya presently serves on the board of directors of BIO and will also be making a Company Presentation. In her presentation, she will highlight Nanoscope's Multi-Characteristic Opsin platform and give an overview of the Company's mutation-agnostic approach. She will also detail the Company's ongoing corporate activities. Nanoscope leadership will be available for meetings during the conference. Details for the presentations are as follows: Session Date: Wednesday, June 5, 2024 Session Time: 4:30 – 4:45 p.m. PT Location: San Diego Convention Center, Company Presentation Theater 1 Presenter: Sulagna Bhattacharya, Co-Founder and Chief Executive Officer About Nanoscope Therapeutics Inc. Nanoscope Therapeutics is developing gene-agnostic, sight-restoring optogenetic therapies for the millions of patients blinded by inherited retinal diseases, for which no cure exists. The company's lead asset, MCO-010, recently announced the 100-week data from the RESTORE Phase 2b/3 multicenter, randomized, double-masked, sham-controlled clinical trial in the U.S. for RP (NCT04945772). The company has also recently completed the Phase 2 STARLIGHT trial of MCO-010 therapy in patients with Stargardt disease (NCT05417126 ). MCO-010 has received FDA fast-track designations and FDA orphan drug designations for both RP and Stargardt disease. Preclinical assets include non-viral laser-delivered MCO-020 gene therapy for geographic atrophies secondary to AMD. For more information visit Nanostherapeutics.com Samarendra Mohanty #BIO2024 #ophthalmology #genetherapy #leadership https://lnkd.in/gy36_Bfh

Last week, we had the honor of hosting Biotechnology Innovation Organization CEO John F. Crowley and the BIO team at Nanoscope Therapeutics Inc. during their national “listening tour” of biotech hubs. It was a pleasure to show John around our Arlington labs and Dallas offices, where he generously met our team and shared his inspiring personal journey. Thank you, John, for the motivation and inspiration!   Later, we were thrilled to host a gathering of over two dozen biotech leaders from the Dallas area. We discussed the challenges and needs of emerging biotech companies in Texas, Oklahoma, and Arkansas with the BIO team. The exchange of ideas for solutions and growth was incredibly valuable.   A big thanks to John Crowley and the BIO team for spending time with us in Dallas! Sulagna Bhattacharya Samarendra Mohanty Kathleen Otto-Rosenblum Khandan Baradaran Michael Marquez BioNTX #biotechnology #Texas #dallas

It was a busy week for Nanoscope Therapeutics Inc. with Association for Research in Vision and Ophthalmology (ARVO), Retina World Congress, and American Society of Gene & Cell Therapy (ASGCT) conferences back-to-back-back. I'm proud of the impact we are making on lives of patients with permanent vision loss. Thank you CGTLive for highlighting our work: https://lnkd.in/emKuCpd8 i2Vision, Inc. Prevent Blindness Foundation Fighting Blindness

Nanoscope Therapeutics Inc. welcomes Khandan Baradaran, PhD, to our team as Senior VP of Regulatory and Quality. Dr. Baradaran brings nearly two decades of extensive experience in manufacturing and regulatory review of gene therapy products, including regulatory Chemistry, Manufacturing, and Controls (CMC) experience.  “Khandan’s experience leading quality and compliance for rare genetic disease biopharmaceutical companies will be valuable as we continue to advance our versatile MCO platform, including MCO-010, which is driving our expanding pipeline of programs. This appointment supports the continued advancement of our mutation-agnostic therapies to restore vision in millions of people blinded by retinal diseases and highlights our continued growth as a company,” said Sulagna Bhattacharya, Co-Founder and Chief Executive Officer of Nanoscope. “I am honored to join the highly motivated team at Nanoscope in the development of its novel approach to treating retinal degenerative diseases,” said Dr. Baradaran. “Following the impressive durable efficacy and safety results from the randomized control trial in retinitis pigmentosa (RP), I eagerly anticipate contributing to Nanoscope's advancement as we navigate forthcoming regulatory milestones and prepare for commercial readiness.” To learn more about Nanoscope Therapeutics and Dr. Baradaran visit nanostherapeutic.com #genetherapy #biotechnology #rarediseases https://lnkd.in/dP5cBbYF

Today (5/9) Nanoscope Therapeutics Inc. President and Chief Scientific Officer Samarendra Mohanty, PhD, made a presentation to the Retina World Congress in Ft. Lauderdale. Later, he participated in a panel discussion moderated by Peter Kaiser, MD. Tomorrow (5/10) Nanoscope MCO-010 Optogenetic Therapy for Retinitis Pigmentosa will also be featured in a presentation by Christine Kay, MD taking place from 2:21 - 2:26pm ET. Title of Dr. Kay’s presentation is: Longitudinal BCVA and Safety Analysis of Mutation-Agnostic MCO-010 Optogenetic Therapy for Retinitis Pigmentosa: Patient Case from A Phase 2b Randomized, Sham-Controlled, Patient and Assessor-Masked Clinical Trial (RESTORE) For more information visit our website: nanostherapeutics.com #ophthalmology #retina #genetherapy #retinitispigmentosa #clinicaltrials.  Sulagna Bhattacharya

Nanoscope Therapeutics Inc.viral and laser-delivered Multi-Characteristic Opsin (MCO) gene therapy platforms will be featured in multiple presentations at the upcoming 2024 American Society of Gene & Cell Therapy Annual Meeting and the Retina World Congress Retina World Congress Details are as follows: ******** ASGCT ******** Abstract Title: Longitudinal Analysis of BCVA and Near-Field Object Recognition in Low- or High-Dose MCO-010 Mutation Agnostic Optogenetic Therapy for Retinitis Pigmentosa: 12-Month Results from a Phase 2b/3 Randomized, Sham-Controlled, Patient- and Assessor-Masked Clinical Trial (RESTORE) Poster Number: 917 Date: May 8, 2024 Time: 12:00 – 7:00 p.m. ET Presenter: Samuel B Barone, MD, Chief Medical Officer ******** Presentation Title: Non-Viral Targeted Laser Delivery of Multi-Characteristic Opsin Genes for Treatment of Geographic Atrophy Presentation # 426 Type: Oral Abstract Session Date: May 11, 2024 Time: 11:15 – 11:30 a.m. ET Presenter: Samarendra Mohanty, PhD, President & Chief Scientific Officer In this talk, Dr. Mohanty will highlight the advancement of near-infrared laser-delivered MCO-020 platform for the treatment of geographic atrophies (GA) secondary to age-related macular degeneration (AMD). ******************************************** Retina World Congress 2024 ******************************************** Title: Gene Therapy, Pharmacotherapy and Optogenetics for IRD Date: May 9, 2024 Time: 9:05 – 9:35 a.m. ET Location: Fort Lauderdale Marriott Harbor Beach Hotel Presenter: Samarendra Mohanty, PhD, Chief Scientific Officer Dr. Mohanty will provide a corporate update on Nanoscope’s mutation-agnostic MCO-010 gene therapy for vision restoration in patients with inherited retinal degenerations (IRDs). This will be followed by a panel discussion moderated by Peter Kaiser, MD, Professor of Ophthalmology at Cole Eye Institute in Cleveland Clinic Lerner College of Medicine. ******** Presentation Title: Longitudinal BCVA and Safety Analysis of Mutation-Agnostic MCO-010 Optogenetic Therapy For Retinitis Pigmentosa: Patient Case From A Phase 2b Randomized, Sham-Controlled, Patient- And Assessor-Masked Clinical Trial (RESTORE) Date: May 10, 2024 Time: 2:21 – 2:26 p.m. ET Location: Fort Lauderdale Marriott Harbor Beach Hotel Presenter: Christine Kay, MD, Director of Electrophysiology, Retinal Genetics, and Clinical Trials at Vitreoretinal Associates in Gainesville, Florida, and Affiliate Assistant Professor at the University of South Florida. Dr. Kay will detail the statistically significant and clinically meaningful improvements in visual acuity observed longitudinally for an individual with advanced retinitis pigmentosa (RP) treated with MCO-010 in the RESTORE trial. ************************************************************ For more details visit our website: nanostherapeutics.com ************************************************************ #ASGCT2024 #Retina #genetherapy #ophthalmology Sulagna Bhattacharya

An exciting, standing-room-only event today at #ARVO2024 as Nanoscope Therapeutics Inc. Chief Medical Advisor, Dr. Allen Ho, made his presentation featuring 12-month results from the Phase 2b/3 RESTORE clinical trial of our lead program, MCO-010, a mutation-agnostic gene therapy for patients with permanent and severe vision loss from advanced #retinitispigmentosa.  ***** Tomorrow 5/7 Nanoscope Chief Medical Officer Dr. Samuel B Barone, makes a poster presentation: Test-retest Agreement of the Freiburg Visual Acuity Test in Ultra-low Vision Poster Number: A0223 Type: Poster Session May 7, 2024 -- 1:15 – 3:00 p.m. PT Exhibit Hall - Seattle Convention Center Presenter: Samuel B Barone, MD, CMO *************************************************************************** Connect with the Nanoscope team at our ARVO exhibit hall booth #4620 Presentation Details available on our website: nanostherapeutics.com *************************************************************************** More ARVO presentations featuring Nanoscope MCO-010 optogenetic gene therapy are scheduled later in the week: ***** Longitudinal BCVA Analysis of Patients with Stargardt Disease and Macular Degeneration Treated With MCO-010, a Mutation-Agnostic Optogenetic Therapy: 48-Week Results From a Phase 2a Clinical Trial (STARLIGHT) Poster Number: B0094 May 8, 2024 -- 2:15 – 4:00 p.m. PT Exhibit Hall - Seattle Convention Center Presenter: Vinit B. Mahajan, MD, PhD, Professor of Ophthalmology, Stanford University ***** Multi-characteristic opsin gene therapy attenuates retinal degeneration and restores vision in mouse models of retinitis pigmentosa Abstract/Poster Number: B0293 May 8, 2024 -- 2:15 – 4:00 p.m. PT Exhibit Hall - Seattle Convention Center Presenter: Subrata Batabyal, PhD, Director, Non-Clinical Development ***** Characterization of a Broadband Ambient Light Activatable Multi-Characteristic Opsin Supporting its Superior Performance in Restoring Vision Poster Number: B0924 Session Date: May 9, 2024 -- 8:00 – 9:45 a.m. PT Exhibit Hall - Seattle Convention Center Presenter: Samarendra Mohanty, PhD, President and CSO ***** In Vivo Efficacy of a Novel Multi-Characteristic Opsin (MCO-010) in a Mouse Model of Leber Congenital Amaurosis Poster Number: B0942 May 9, 2024 -- 8:00 – 9:45 a.m. PT Exhibit Hall - Seattle Convention Center Presenter: Naj Sharif, PhD, DSC, VP of Global Research and Development Details for all presentations are below and on our website: nanostherapeutics.com #ophthalmology #optogenetics #retina Association for Research in Vision and Ophthalmology (ARVO) Sulagna Bhattacharya